Insulin Pump Versus Multiple Daily Insulin Injections

Investigators from multiple institutions in the United Kingdom conducted a randomized trial to compare the efficacy and costs of using continuous subcutaneous insulin infusion (CSII) or multiple daily injection (MDI) insulin regimens for the treatment of children with newly diagnosed type 1 diabetes. Children 7 months to 15 years old seen at 1 of 15 centers in England and Wales with a new diagnosis of type 1 diabetes were eligible for the study. At enrollment, participants were randomized to CSII or MDI. Insulin treatment was started within 14 days of diagnosis and consisted of insulin aspart for children randomized to CSII, and short-acting insulin analogue insulin aspart and long-acting insulin analogue, either insulin glargine or detemir, for those randomized to MDI. At baseline, hemoglobin A1c (HbA1c) levels were measured. Patients were enrolled in the study …